<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112553</url>
  </required_header>
  <id_info>
    <org_study_id>2009-P-002689</org_study_id>
    <secondary_id>400483</secondary_id>
    <nct_id>NCT01112553</nct_id>
  </id_info>
  <brief_title>Treximet Migraine Brain Imaging Research Study</brief_title>
  <acronym>TREX</acronym>
  <official_title>Evaluation of Brain Activation in Complete Responders and Partial Responders Following Acute Administration of Treximet (Sumatriptan and Naproxen)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <brief_summary>
    <textblock>
      We are looking for volunteers who suffer from acute migraine (&lt;14 episodes per month) to&#xD;
      participate in a 2-visit brain imaging research study. The goal of the study is to observe&#xD;
      the effect of acute administration of Treximet during a migraine episode on the pain pathways&#xD;
      of the migraine brain. Visit 1 will consist of 1 hour, where participants will be signing the&#xD;
      informed consent form, completing questionnaires, meeting with the study physician, and&#xD;
      having QST (sensory testing to determine individual pain thresholds to a heat stimulus)&#xD;
      performed. Visit 2 will occur during a migraine episode. Volunteers will be asked to contact&#xD;
      the study team at the first onset of a migraine. Upon arrival at Visit 2, individuals will be&#xD;
      given an IV for blood draws. Once these the IV is in place, subjects will enter the MRI and&#xD;
      be asked to stay very still. Scanning will occur for about 20 minutes, and then subjects will&#xD;
      be given a Treximet tablet to combat their migraine. More scanning will follow Treximet&#xD;
      administration. Some scans will have no stimulation, and others will apply a heat stimulus&#xD;
      that subjects will rate using a pain scale. Seven 5-mL blood samples will be drawn throughout&#xD;
      the duration of the MRI session. Both Visit 1 and Visit 2 will be compensated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was closed due to low enrollment numbers.&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Treximet</arm_group_label>
    <description>All migraine subjects will receive Treximet during a migraine episode at Visit 2.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Seven 5-mL blood samples will be drawn throughout the MRI session, and blood plasma will be&#xD;
      analyzed for the concentration of Treximet.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        English-speaking males or females between the ages of 18 and 65, who suffer from acute&#xD;
        migraine (&lt;14 migraine episodes/ month), will be recruited for this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female (not pregnant or nursing)&#xD;
&#xD;
          -  Age 18-65; with a focus on age 30-40 years&#xD;
&#xD;
          -  Episodic migraine (experience migraine headache &lt;14 days out of the month), with focus&#xD;
             on left-sided pain&#xD;
&#xD;
          -  Currently taking Treximet routinely for migraine treatment&#xD;
&#xD;
          -  No significant medical history (No illnesses such as seizure disorder, diabetes,&#xD;
             alcoholism, cardiac disease including coronary artery disease, psychiatric problems;&#xD;
             drug addiction, respiratory problems, liver disease, etc.)&#xD;
&#xD;
          -  No significant medication history, except for migraine&#xD;
&#xD;
          -  Weight, &lt;285 pounds&#xD;
&#xD;
          -  Not claustrophobic&#xD;
&#xD;
          -  No contraindication to taking triptans&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 or &gt; 65&#xD;
&#xD;
          -  Significant medical problems (aside from pain before, during and after migraine&#xD;
             episodes)&#xD;
&#xD;
          -  Positive drug of abuse screen (excluding medications currently prescribed for their&#xD;
             clinical condition, e.g. opioids, benzodiazepines, etc.)&#xD;
&#xD;
          -  Use of opioid medications&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  History of dermatological hypersensitivity in the facial area&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Sensory loss detected on Quantitative Sensory Testing at screening&#xD;
&#xD;
          -  Significant alcohol history (ingestion of 5 or more glasses (&gt; 40 oz) of alcohol per&#xD;
             week)&#xD;
&#xD;
          -  Metal implants of any type (including dental bridges, crowns, retainers, orthodontic&#xD;
             devices e.g. braces, etc.)&#xD;
&#xD;
          -  Tattoos containing metallic ink on the neck, shoulders, upper arm and head (which&#xD;
             could become heated up in the scanner, and potentially cause blistering or burning)&#xD;
&#xD;
          -  Cardiac pacemakers&#xD;
&#xD;
          -  Aneurysm clips and other vascular stents, filters, clips or other devices&#xD;
&#xD;
          -  Prosthetic heart valves&#xD;
&#xD;
          -  Other prostheses&#xD;
&#xD;
          -  Neuro-stimulator devices&#xD;
&#xD;
          -  Implanted infusion pumps&#xD;
&#xD;
          -  Cochlear (ear) implants&#xD;
&#xD;
          -  Ocular (eye) implants or known metal fragments in eyes&#xD;
&#xD;
          -  Exposure to shrapnel or metal filings (sheet metal workers, welders, and others)&#xD;
&#xD;
          -  Other metallic surgical hardware in vital areas&#xD;
&#xD;
          -  Any known allergic side effects to Treximet&#xD;
&#xD;
          -  Use of any of the following medications:&#xD;
&#xD;
          -  Monoamine Oxidase A- Inhibitors (Azilect, Eldepryl, Marplan, Nardil, Parnate, Zelapar)&#xD;
&#xD;
          -  SSRI's: citalopram/ Celexa, Lepraxo, paroxetine/ Paxil, fluoxetine/ Prozac, Sarafem,&#xD;
             Symbyax, Sertraline/ Zoloft, Fluvoxamine/ Luvox&#xD;
&#xD;
          -  SNRI's: duloxetine/ Cymbalta, venlafaxine/ Effexor&#xD;
&#xD;
          -  Triptans: sumatriptan/ Imitrex, naratriptan/ Amerge, zolmitriptan/ Zomig, rizatriptan/&#xD;
             Maxalt, eletriptan/ Relpax, almotriptan/ Axert&#xD;
&#xD;
          -  Ergotamine type medicines: Bellergal, Cafergot, Ergomar, Wiraine, Migranal/ DHE45,&#xD;
             Sansert&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Borsook, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neuroimaging Center, McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>October 30, 2012</last_update_submitted>
  <last_update_submitted_qc>October 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>David Borsook, MD, PhD</investigator_full_name>
    <investigator_title>Senior Research Associate</investigator_title>
  </responsible_party>
  <keyword>Acute Migraine</keyword>
  <keyword>Treximet</keyword>
  <keyword>Imaging</keyword>
  <keyword>fMRI</keyword>
  <keyword>Pain</keyword>
  <keyword>Heat Stimulus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

